Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN)
CUSIP: 53630X203
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 8,072,317
- Total 13F shares
- 528,456
- Share change
- +10,983
- Total reported value
- $1,670,206
- Price per share
- $3.16
- Number of holders
- 18
- Value change
- +$34,959
- Number of buys
- 6
- Number of sells
- 8
Quarterly Holders Quick Answers
What is CUSIP 53630X203?
CUSIP 53630X203 identifies LPCN - Lipocine Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 53630X203:
Top shareholders of LPCN - Lipocine Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
2.8%
|
226,276
|
$719,557 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
1.1%
|
89,272
|
$283,885 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.73%
|
58,834
|
$187,125 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.48%
|
38,980
|
$123,956 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.46%
|
37,510
|
$119,282 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.31%
|
24,935
|
$79,293 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.23%
|
18,626
|
$59,231 | — | 31 Mar 2025 | |
| Morgan R. Brown |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
176,000
|
$46,746 | — | 07 Dec 2021 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.16%
|
13,160
|
$41,849 | — | 31 Mar 2025 | |
| Jeffrey Arvin Fink |
3/4/5
|
Director |
—
class O/S missing
|
11,526
|
$36,883 | — | 04 Jun 2025 | |
| Richard Dana Ono |
3/4/5
|
Director |
—
class O/S missing
|
11,526
|
$36,883 | — | 04 Jun 2025 | |
| George Nomikos |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
125,000
|
$33,200 | — | 01 Nov 2022 | |
| Jill M. Jene |
3/4/5
|
Director |
—
class O/S missing
|
7,174
|
$22,956 | — | 04 Jun 2025 | |
| Spyros Papapetropoulos |
3/4/5
|
Director |
—
class O/S missing
|
7,174
|
$22,956 | — | 04 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
2,581
|
$8,207 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.03%
|
2,575
|
$8,188 | — | 31 Mar 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.03%
|
2,246
|
$7,141 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
1,237
|
$3,934 | — | 31 Mar 2025 | |
| CALDWELL SUTTER CAPITAL, INC. |
13F
|
Company |
0.01%
|
471
|
$1,498 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0%
|
237
|
$754 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
199
|
$632 | — | 31 Mar 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
197
|
$626 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
67
|
$213 | — | 31 Mar 2025 | |
| Tidemark, LLC |
13F
|
Company |
0%
|
59
|
$188 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
11
|
$35 | — | 31 Mar 2025 |
Institutional Holders of Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN) as of Q2 2025
As of 30 Jun 2025,
Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
528,456 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, DIMENSIONAL FUND ADVISORS LP, STATE STREET CORP, NORTHERN TRUST CORP, BARCLAYS PLC, and BANK OF AMERICA CORP /DE/.
This page lists
18
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
19
Q2 2025 holders
18
Holder diff
-1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.